Prof Paul Kubler, Australia
The Celltrion Satellite Symposium, “Redefining your practice with infliximab biosimilar,” will highlight the role of biosimilar infliximab in expanding treatment options in rheumatologic diseases by introducing a novel subcutaneous formulation of infliximab.
The symposium will be chaired by Prof. Paul Kubler from Australia and will explore three key areas:
- BIO-SWITCH study: biosimilar infliximab experience in a single centre in the Netherlands
Speaker: Prof. Frank van den Hoogen from the Netherlands will discuss how biosimilars can offer healthcare providers and patients greater treatment choice and value, better access to treatments and improved patient outcomes
- Drug retention of infliximab in Rheumatoid arthritis: Data from KOBIO
Speaker: Prof. Kichul Shin from South Korea will discuss the retention rate and safety of CT-P13 in patients with rheumatoid arthritis based on the data from KOBIO, the largest biologics and targeted therapy registry in South Korea.
- Future of infliximab: subcutaneous formulation
Speaker: Prof Daehyun Yoo from South Korea will reveal the latest clinical data on the efficacy and safety of subcutaneous infliximab.
The symposium will close with a panel discussion which will allow the audience to ask questions.
|Wednesday 10 April 2019|
|1030 – 1035||Welcome and Introduction||Prof Paul Kubler|
|1035 – 1055||BIO-SWITCH study: biosimilar infliximab experience in a single centre in the Netherlands||Prof. Frank van den Hoogen|
|1055 – 1115||Drug retention of infliximab in Rheumatoid arthritis: Data from KOBIO||Prof Ki-Chul Shin|
|1115 – 1135||Future of infliximab: subcutaneous formulation||Prof Dae Hyun Yoo|
|1135 – 1145||Panel Discussion||All|